|
|
 |
 Since its founding in 1820, The New York Eye and Ear Infirmary mission has been for excellence in patient care for eye disease as well as education of eye care providers. To maintain excellence, research must be an integral part of this mission.
Researchers at The New York Eye and Ear Infirmary were among the first to use the laser in treating retinal diseases. Today, the Department of Ophthalmology maintains a strong
commitment to medical research, which contribute to advances in Ophthalmology and related areas of medicine.
Research of medical practitioners is facilitated by a staff of research scientists, neuro-ophthalmolgists, pathologists, and electrophysiologists, who likewise conduct independent research in their respective areas.
The New York Eye and Ear Infirmary continues to be involved in many clinical and translational research projects. This site makes information about these trials available to all. The active protocols have information about:
- the issue being studied and goal for the research
- inclusion and exclusion criteria
- contact person
- other pertinent information
For results of previous studies, go to www.clinicaltrials.gov
To
browse current clinical trials in Ophthalmology, choose a research
specialty:
Bacterial
Conjunctivitis | Glaucoma
| Ocular
Cancer (Oncology) | Ocular Trauma
| Oculopastic & Orbital Surgery | Ophthalmology
Safety | Refractive Surgery |
Retina
| Uveitis
Want more
information about Ophthalmology Research?
|
|
|
|
Bacterial
Conjunctivitis (Pink Eye) |
|
Study/Title |
Principal
Investigator |
|
A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox™ in the Treatment of Bacterial Conjunctivitis |
Lois
McNally, MD |
|
Glaucoma |
|
A One Year, Investigator-Masked, Prospective, Randomized, Naturalistic, Observational Study of the Safety and Efficacy of
Lumigan, Xalatan and Travatan in the Management of Elevated IOP in Patients with Open-Angle Glaucoma and Ocular Hypertension |
Paul
Sidoti, MD |
|
Ocular
Oncology |
|
The Collaborative Ocular Melanoma Study |
Paul
Finger, MD |
|
Ocular
Trauma |
|
Trauma Registry |
|
|
Oculoplastic
& Orbital Surgery |
|
Thyroid Eye Disease
Study |
Robert
Della Rocca, MD
Paul Latkany, MD |
|
Ophthalmology
Safety |
|
A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients |
Alessandra
Bertolucci, MD |
|
Refractive
Surgery |
|
SRP (Surgical Reversal of
Presbyopia) |
Barrie
Soloway, MD |
|
Retina |
|
Retinal
Imaging |
|
Comparison of
OCT-Opthalmoscope and Standard OCT Technology Instrument For the Imaging of Macular Hole Pathology |
Richard
Rosen, MD |
|
Macular Pigment Density Measurements Using Auto Fluorescence HRA |
Richard
Rosen, MD |
|
Central
Retinal Vein Occlusion (CRVO) |
|
The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study |
Richard
Rosen, MD
Belinda Shirkey, MD |
|
Diabetic
Macular Edema |
|
A 3-Year, Phase 3,
Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System
(DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema |
Richard
Rosen, MD |
|
Age
Related Macular
Degeneration |
|
The Age-Related Eye Disease Study II
(AREDS II): A Multi-center, Randomized Trial of Lutein, Zeaxanthin, and Long-Chain Omega-3 Fatty Acids
(Docosahexaenoic acid [DHA] and Eicosapentaenoic acid [EPA]) in Age-Related Macular Degeneration |
Richard
Rosen, MD |
|
A
Phase IV, Open Label, Multi-Center, Trial of Maintenance Intravitreous
Injections of Macugen® (Pegaptanib Sodium) Given Every 6 Weeks for 48
Weeks in Subjects with Subfoveal Neovascular Age-Related Macular
Degeneration (AMD) Initially Treated with a Modality Resulting in
Maculopathy Improvement, EOP 1023 |
Richard
Rosen, MD |
|
New A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration- (CLEAR IT 3) |
Richard
Rosen, MD |
|
New A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD) - ACU301B |
Richard
Rosen, MD |
|
New Serial Retinal Thickness Changes and Scotoma Size Measured with Lucentis Therapy measured Using the OCT Ophthalmoscope (OCT/SLO)® and the Foresee Preferential Hyperacuity Perimeter TM PROTOCOL FVF4193s |
Richard
Rosen, MD |
|
New A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration |
Richard
Rosen, MD |
|
Macular Telangiectasia |
|
A Natural History Study Of Macular
Telangiectasia- The MacTel Study |
Richard
Rosen, MD |
|
Uveitis |
|
Uveitis Genetics |
C.
Michael Samson, MD |
|
An 8-Week,
Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System
(DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with
Intermediate Uveitis |
C.
Michael Samson, MD |
|
A 6-Week,
Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System
(DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Anterior Segment in Patients with
Anterior Uveitis |
C.
Michael Samson, MD |
|
Multicenter Uveitis Steroid Treatment Trial (MUST) |
Paul
Latkany, MD |
|
The Use of Confocal Microscopy to Characterise Keratic Precipitates
(KPs) in Sarcoidosis- Associated Uveitis |
C.
Michael Samson, MD
Samir, Tari, MD |
|
Quantification of the Effect of Free Radicals in Sera and Tear Films of Uveitic Patients |
C.
Michael Samson, MD
Samir, Tari, MD |
|
 TOP
|
|
|
|
|
NYEE
Eye Research Centers
Aborn
Eye Research Center
Among
this active research lab's discoveries is the invention of the first modern system of corneal
topography, now manufactured commercially as the Topographic Modeling System
(TMS).
Advanced Retinal Imaging Laboratory
This
specialty facility explores new technologies for imaging the human retina
in order to enhance our understanding of the anatomy, physiology and
visual function.
Glaucoma Services
Clinical
service at the forefront of innovation in diagnostic and therapeutic advances
in the understanding and treatment of glaucoma.
Ocular
Pathology Laboratory
A
major referral center for the Metropolitan area and the Northeastern US.
The New York Glaucoma Institute
Created
to support research into the basic causes of glaucoma, increase public
awareness of glaucoma, and promulgate educational material for
ophthalmologists, other physicians, and persons with glaucoma.
The Ocular Imaging Center
Ultrasound
Biomicroscopy (UBM) and Optical Coherence Tomography (OCT) clinical databases.
New York Medical
College
Additional
research facilities are located amongst affiliated hospitals and universities of the academic
department.
TOP
|
|
Printer-Friendly Page
Large Print Version